Lorvotuzumab provides a CD56-targeting monoclonal antibody for cancer and antibody research. It recognizes CD56, also known as neural cell adhesion molecule 1 (NCAM1), a cell-surface protein expressed in certain neuroendocrine tumors and hematologic malignancies and specifically supports studies of tumor antigen recognition, antibody-mediated targeting, and antibody-drug conjugate (ADC) development.
Key Features and Benefits
- CD56-Targeting Antibody: Recognizes CD56/NCAM1, a cell-surface glycoprotein specifically involved in cell adhesion and cellular interactions.
- Monoclonal Antibody Design: Provides an antibody platform specifically for investigating CD56 recognition and tumor cell targeting.
- CD56 Recognition: Supports investigation of CD56 expression, antibody binding, internalization, and antigen-specific cellular interactions.
- Tumor Cell Targeting: Enables studies of antibody binding to CD56-expressing cancer cells.
- ADC Development Platform: Provides the antibody component specifically associated with Lorvotuzumab Mertansine (IMGN901), an investigational CD56-directed ADC.
- Cellular Internalization Research: Supports investigation of antibody uptake and intracellular trafficking in CD56-expressing cells.
- Neuroendocrine Tumor Research: Useful for studying CD56 as a tumor-associated marker in neuroendocrine malignancies.
- Antibody Engineering Research: Supports investigation of antibody conjugation, antigen specificity, and targeted payload delivery strategies.
Applications
- Small Cell Lung Cancer Research: Supports investigation of CD56-targeted antibody strategies in small cell lung cancer models.
- Multiple Myeloma Research: Especially useful for studying CD56 expression and antibody targeting in relevant multiple myeloma cell models.
- Neuroendocrine Cancer Research: Supports investigation of CD56 recognition and tumor-associated antigen expression in neuroendocrine cancer models.
- CD56-Positive Cancer Research: Useful for evaluating antibody binding and cellular responses in CD56-expressing tumor cells.
- Tumor Antigen Research: Supports studies of CD56/NCAM1 expression and its role in cancer cell biology.
- ADC Research: Provides a targeting antibody platform for investigating CD56-directed payload conjugation and delivery.
- Antibody Binding Assays: Useful for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in CD56-expressing cells.
- Comparative Antibody Research: Useful for comparing CD56-targeting antibodies and antibody-mediated cancer cell recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Lorvotuzumab provides a CD56-directed monoclonal antibody for investigating tumor-associated antigen recognition and targeted cancer cell binding and specifically supports small cell lung cancer, multiple myeloma, neuroendocrine tumor, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
